These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 17119036)

  • 41. Association of p53 polymorphisms with breast cancer: a case-control study in Slovak population.
    Franeková M; Zúbor P; Stanclová A; Dussan CA; Bohusová T; Galo S; Dobrota D; Kajo K; Péc M; Racay P
    Neoplasma; 2007; 54(2):155-61. PubMed ID: 17319790
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Associations of matrix metalloproteinase-9 protein polymorphisms with lymph node metastasis but not invasion of gastric cancer.
    Tang Y; Zhu J; Chen L; Chen L; Zhang S; Lin J
    Clin Cancer Res; 2008 May; 14(9):2870-7. PubMed ID: 18451255
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CYP19A1 gene polymorphisms and risk of lung cancer.
    Zhang J; Yin Y; Niu XM; Liu Y; Garfield D; Chen SF; Wang R; Wang L; Chen HQ
    J Int Med Res; 2013 Jun; 41(3):735-42. PubMed ID: 23669293
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A common polymorphism in the human aromatase gene alters the risk for polycystic ovary syndrome and modifies aromatase activity in vitro.
    Wang H; Li Q; Wang T; Yang G; Wang Y; Zhang X; Sang Q; Wang H; Zhao X; Xing Q; Shi J; He L; Wang L
    Mol Hum Reprod; 2011 Jun; 17(6):386-91. PubMed ID: 21282199
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CYP1A2--a novel genetic marker for early aromatase inhibitor response in the treatment of breast cancer patients.
    Simonsson M; Veerla S; Markkula A; Rose C; Ingvar C; Jernström H
    BMC Cancer; 2016 Mar; 16():256. PubMed ID: 27029552
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women.
    Haiman CA; Dossus L; Setiawan VW; Stram DO; Dunning AM; Thomas G; Thun MJ; Albanes D; Altshuler D; Ardanaz E; Boeing H; Buring J; Burtt N; Calle EE; Chanock S; Clavel-Chapelon F; Colditz GA; Cox DG; Feigelson HS; Hankinson SE; Hayes RB; Henderson BE; Hirschhorn JN; Hoover R; Hunter DJ; Kaaks R; Kolonel LN; Le Marchand L; Lenner P; Lund E; Panico S; Peeters PH; Pike MC; Riboli E; Tjonneland A; Travis R; Trichopoulos D; Wacholder S; Ziegler RG
    Cancer Res; 2007 Mar; 67(5):1893-7. PubMed ID: 17325027
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.
    Leyland-Jones B; Gray KP; Abramovitz M; Bouzyk M; Young B; Long B; Kammler R; Dell'Orto P; Biasi MO; Thürlimann B; Lyng MB; Ditzel HJ; Harvey VJ; Neven P; Treilleux I; Rasmussen BB; Maibach R; Price KN; Coates AS; Goldhirsch A; Pagani O; Viale G; Rae JM; Regan MM
    Breast Cancer Res Treat; 2015 Jun; 151(2):373-84. PubMed ID: 25935582
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Genetic variation in ALCAM and other chromosomal instability genes in breast cancer survival.
    Varadi V; Bevier M; Grzybowska E; Johansson R; Enquist-Olsson K; Henriksson R; Butkiewicz D; Pamula-Pilat J; Tecza K; Hemminki K; Lenner P; Försti A
    Breast Cancer Res Treat; 2012 Jan; 131(1):311-9. PubMed ID: 21935604
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Genetic variation in CYP19A1 and risk of breast cancer and fibrocystic breast conditions among women in Shanghai, China.
    Chen C; Sakoda LC; Doherty JA; Loomis MM; Fish S; Ray RM; Lin MG; Fan W; Zhao LP; Gao DL; Stalsberg H; Feng Z; Thomas DB
    Cancer Epidemiol Biomarkers Prev; 2008 Dec; 17(12):3457-66. PubMed ID: 19064562
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Association of CYP19A1 gene variations with adjuvant letrozole-induced adverse events in South Indian postmenopausal breast cancer cohort expressing hormone-receptor positivity.
    Umamaheswaran G; Kadambari D; Muthuvel SK; Kalaivani S; Devi J; Damodaran SE; Pradhan SC; Dubashi B; Dkhar SA; Adithan C
    Breast Cancer Res Treat; 2020 Jul; 182(1):147-158. PubMed ID: 32385792
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Soyfood intake and breast cancer survival: a followup of the Shanghai Breast Cancer Study.
    Boyapati SM; Shu XO; Ruan ZX; Dai Q; Cai Q; Gao YT; Zheng W
    Breast Cancer Res Treat; 2005 Jul; 92(1):11-7. PubMed ID: 15980986
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Interaction between CYP19A1 polymorphisms and body mass index in the risk of endometrial cancer in postmenopausal Japanese women.
    Hosono S; Matsuo K; Ito H; Watanabe M; Hirose K; Nakanishi T; Tajima K; Tanaka H
    Asian Pac J Cancer Prev; 2011; 12(10):2747-52. PubMed ID: 22320986
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The
    Lv F; Huang W; Wang Y
    Genet Test Mol Biomarkers; 2021 Jul; 25(7):486-495. PubMed ID: 34280004
    [No Abstract]   [Full Text] [Related]  

  • 54. A CYP19 (aromatase) polymorphism is associated with increased premenopausal breast cancer risk.
    Talbott KE; Gammon MD; Kibriya MG; Chen Y; Teitelbaum SL; Long CM; Gurvich I; Santella RM; Ahsan H
    Breast Cancer Res Treat; 2008 Oct; 111(3):481-7. PubMed ID: 17975727
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of functional genetic polymorphisms in the CYP19A1 gene on prostate cancer risk and survival.
    Kanda S; Tsuchiya N; Narita S; Inoue T; Huang M; Chiba S; Akihama S; Saito M; Numakura K; Tsuruta H; Satoh S; Saito S; Ohyama C; Arai Y; Ogawa O; Habuchi T
    Int J Cancer; 2015 Jan; 136(1):74-82. PubMed ID: 24803183
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trial.
    Fontein DB; Houtsma D; Nortier JW; Baak-Pablo RF; Kranenbarg EM; van der Straaten TR; Putter H; Seynaeve C; Gelderblom H; van de Velde CJ; Guchelaar HJ
    Breast Cancer Res Treat; 2014 Apr; 144(3):599-606. PubMed ID: 24590773
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Association of CYP19A1 gene rs7176005 single nucleotide polymorphism with breast cancer risk and clinicopathologic features of tumor].
    Du ZG; Wang LY; Zhou Y; Wan HY; Liang FQ; Lyu Q
    Zhonghua Yu Fang Yi Xue Za Zhi; 2018 Aug; 52(8):827-832. PubMed ID: 30107717
    [No Abstract]   [Full Text] [Related]  

  • 58. Significant survival impact of MACC1 polymorphisms in HER2 positive breast cancer patients.
    Muendlein A; Hubalek M; Geller-Rhomberg S; Gasser K; Winder T; Drexel H; Decker T; Mueller-Holzner E; Chamson M; Marth C; Lang AH
    Eur J Cancer; 2014 Aug; 50(12):2134-41. PubMed ID: 24910416
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Epistasis between FSHR and CYP19A1 polymorphisms is associated with premature ovarian failure.
    Kim S; Pyun JA; Cha DH; Ko JJ; Kwack K
    Fertil Steril; 2011 Jun; 95(8):2585-8. PubMed ID: 21269619
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Given breast cancer, is fat better than thin? Impact of the estrogen receptor beta gene polymorphisms.
    Borgquist S; Hjertberg M; Henningson M; Ingvar C; Rose C; Jernström H
    Breast Cancer Res Treat; 2013 Feb; 137(3):849-62. PubMed ID: 23274843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.